Aspirin Use in Patients with Colorectal Cancer

Article

Among long-term CRC survivors, regular use of aspirin is associated with overall survival and use of NSAIDs was significantly associated with improved survival only in individuals with KRAS wild-type tumors.

Aspirin use is significantly associated with improved overall survival following a colorectal cancer (CRC) diagnosis. To learn more about which patients benefit most, researchers at cancer treatment centers around the United States conducted a study on the timing of aspirin use in relation to subtypes of CRC.

Cancer registries were used to identify 2419 patients aged 18-74 years who were diagnosed with invasive CRC from 1997 to 2008. Epidemiologic questionnaires were completed at study enrollment and at 5-year follow-ups, and national death registries were used to identify survival outcomes.

After a median of 10.8 years of follow-up after CRC diagnosis, 100 deaths due to CRC were identified. Compared with nonusers, aspirin-only users had more favorable overall survival. Use of any NSAID after diagnosis was associated with improved overall survival only among patients with KRAS wild-type tumors.

The researchers concluded that among long-term CRC survivors, regular use of aspirin is associated with overall survival and use of NSAIDs was significantly associated with improved survival only in individuals with KRAS wild-type tumors. The study findings are available here.

Recent Videos
Karyn Goodman
Expert in oncology
Expert in oncology
Experts in oncology
Expert in oncology
Expert in oncology
Expert in oncology
Expert in oncology
Experts in oncology
Related Content
© 2024 MJH Life Sciences

All rights reserved.